Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

759
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
759
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

344
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
344
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

314
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
314
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

261
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
261
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

348
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
348
Hepatitis01:25

Hepatitis

55
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
55
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Cardiovascular Medicine And Haematology
  9. Haematology
  11. Causal Relationship Between Hepatic Function Indicators And Thrombocytopenia Risk In Early-stage Hepatitis B Virus Infection: Evidence From Clinical Observational Studies And Mendelian Randomization Analyses

Causal relationship between hepatic function indicators and thrombocytopenia risk in early-stage hepatitis B virus infection: evidence from clinical observational studies and mendelian randomization analyses

Tian-Bin Chen1,2, Jian-Wei Jiang3, Hong-Yan Guo4

  • 1The First Affiliated Hospital of Fujian Medical University, Fujian Key Laboratory of Laboratory Medicine, School of Medical Technology and Engineering, Fujian Medical University, Fuzhou, China.

Frontiers in Immunology
|June 13, 2025

Related Experiment Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

3.2K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.2K

View abstract on PubMed

Summary
This summary is machine-generated.

Hepatitis B virus (HBV) infection can cause thrombocytopenia even before liver cirrhosis. This study found that elevated alanine aminotransferase (ALT) levels causally increase thrombocytopenia risk in HBV patients.

Area of Science:

  • Hepatology
  • Virology
  • Hematology
  • Genetics

Background:

  • Thrombocytopenia is common in hepatitis B virus (HBV) infection, occurring even before liver cirrhosis.
  • The molecular mechanisms of HBV-related thrombocytopenia are not fully understood.
  • Investigating hepatic function indicators' role in thrombocytopenia is crucial.

Purpose of the Study:

  • To determine if common hepatic function indicators causally influence thrombocytopenia in HBV infection.
  • To explore the relationship between HBV, liver function, and platelet count.

Main Methods:

  • Retrospective analysis of 16,464 health screening participants.
  • Integration of clinical observational studies and Mendelian randomization (MR) analyses.
Keywords:
HBV: hepatitis B virusHCV: hepatitis C virusIV: instrumental variableMR: mendelian randomization

Related Experiment Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

3.2K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.2K
  • Logistic regression and propensity score matching were used.

    • Main Results:

    • Hepatitis B surface antigen (HBsAg)-positive individuals had higher thrombocytopenia prevalence.
    • Lower albumin and higher ALT, alkaline phosphatase, and total bilirubin were associated with thrombocytopenia.
    • Mendelian randomization confirmed ALT's causal effect on thrombocytopenia risk.

    Conclusions:

    • Multiple hepatic function indicators are linked to thrombocytopenia risk in HBV infection.
    • Alanine aminotransferase (ALT) has a confirmed causal effect on thrombocytopenia risk.
    • These findings highlight ALT as a key indicator of thrombocytopenia risk in early HBV infection.
    RCT: randomized controlled trial
    TPO: thrombopoietin
    single-nucleotide polymorphisms
    snps